Background
Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive and treatment-resistant cancers. A major reason for this poor prognosis is that PDA often creates a highly suppressive tumor microenvironment, meaning the cancer not only grows aggressively but also actively blocks the immune system from recognizing and attacking it. Researchers have been paying increasing attention to a group of cancer-associated mucins, sometimes called oncomucins, especially MUC4, MUC16, and MUC5AC. These large, heavily glycosylated membrane proteins are normally limited in healthy tissue, but they become progressively overexpressed in pancreatic cancer.
Mucins are important because they can influence how cancer cells stick, signal, invade, and evade immune surveillance. However, most earlier work studied each mucin separately. This study examined their combined behavior, or “oncomucinome,” and asked a clinically important question: how do these mucins shape immune suppression in pancreatic cancer, and can targeting them improve response to KRAS G12D inhibition?
Study design and methods
The investigators combined several complementary approaches. They analyzed single-cell RNA sequencing data from 34 samples to map the diversity of oncomucin-expressing cancer cells. They also used multiplex and sequential immunostaining to locate these cells and characterize the immune cells around them. To better understand causality, the team used murine models of pancreatic cancer, including autochthonous models that develop tumors in their native tissue environment.
To study immune suppression, they used NanoString gene expression profiling and gene silencing experiments. Finally, they tested a pharmacologic approach to target oncomucins, using istradefylline, in combination with MRTX1133, a KRAS G12D inhibitor, in a syngeneic mouse model where the immune system remains intact. This combination strategy is especially relevant because KRAS G12D is a key driver mutation in many pancreatic cancers, yet KRAS inhibition alone may be limited by adaptive resistance mechanisms, including immune escape.
Key findings: oncomucins are diverse and linked to poor survival
The study found that oncomucins show extensive clonal diversity in pancreatic ductal adenocarcinoma. In other words, not all tumor cells express the same mucin pattern, and different subclones appear to behave differently. Importantly, oncomucin-expressing populations were associated with a survival disadvantage in PDA, with a highly significant P value of .00013.
Two subpopulations, those enriched for MUC4 and MUC16, became more prominent after stage IIA/B disease. This suggests that as pancreatic cancer progresses, these mucin-positive clones may be selected for because they provide a biological advantage, likely through increased survival and immune evasion.
How oncomucins drive immune suppression
A major observation was that deleting oncomucin-expressing subpopulations significantly reduced the expression of immune checkpoints. Immune checkpoints are molecules that act like brakes on the immune system. Cancer cells often exploit them to avoid being killed by T cells. In this study, removal of oncomucin-positive cells reduced VISTA and TIM3 expression strongly, with P values of <.0001 and .001, and it also increased immune infiltration into tumors.
Specifically, the tumors showed more CD8+ T-cell infiltration, which is important because CD8+ T cells are among the main immune cells responsible for killing cancer cells. There was also increased infiltration of antigen-presenting cells, including macrophages and dendritic cells. These cells help initiate and coordinate immune responses, so their presence suggests a more active antitumor immune environment.
Mechanistic insight: EGFR and UNC5B signaling
The researchers then explored how oncomucins suppress immunity at the molecular level. They found that the oncomucin-positive subpopulations enhance EGFR and UNC5B signaling. EGFR, or epidermal growth factor receptor, is a well-known growth and survival pathway in many cancers. UNC5B is a guidance receptor that can also influence cell behavior and signaling in the tumor setting.
Together, these signaling pathways appear to upregulate multiple immune checkpoints, including VISTA and PD-L1. This is an important finding because it connects a structural tumor feature, mucin overexpression, to a functional immune-evasion program. In simple terms, the mucins are not just markers of aggressive disease; they are active participants in creating a shield that makes the tumor less visible to the immune system.
Interaction with KRAS G12D inhibition
A particularly clinically relevant result emerged when the investigators treated tumors with MRTX1133, a selective KRAS G12D inhibitor. KRAS G12D is one of the most common oncogenic drivers in pancreatic cancer, and inhibiting it is a promising therapeutic strategy. However, the study found that KRAS G12D inhibition increased the expression of oncomucin-positive subpopulations, especially MUC4 and MUC16. This suggests that the tumor may adapt to KRAS blockade by becoming more dependent on immune-suppressive mucin programs.
This adaptive response may help explain why targeted therapy alone may not be enough in pancreatic cancer. As the cancer cell growth pathway is blocked, the tumor appears to compensate by strengthening immune evasion. This is a common pattern in oncology: when one pathway is inhibited, the cancer can activate alternative survival mechanisms.
Combination therapy improved treatment response
The most encouraging part of the study was that pharmacologic targeting of oncomucins improved the efficacy of MRTX1133. In the combination group, investigators observed reduced tumor burden, with a P value of .034. They also saw lower expression of immune checkpoints both locally within the tumor and systemically, including VISTA and TIM3, and reduced Unc5b expression.
These findings suggest that dual targeting may be more effective than targeting KRAS G12D alone. By suppressing both the oncogenic driver and the immunosuppressive mucin network, the treatment appears to create a more permissive immune environment while also limiting tumor growth.
Clinical meaning
This study has several important implications for pancreatic cancer research and therapy. First, it identifies transmembrane oncomucins as active immune regulators rather than passive tumor markers. Second, it suggests that mucin-positive subclones may become more important as disease advances, especially after stage IIA/B. Third, it shows that the tumor’s immune escape machinery can be partially reversed by targeting the oncomucin axis.
From a treatment perspective, the findings support combination approaches for PDA. KRAS G12D inhibition alone may not fully control the disease if the tumor rapidly responds by increasing mucin-driven immune suppression. Adding an oncomucin-targeting strategy may help prevent or delay this escape. Although istradefylline is best known as an adenosine A2A receptor antagonist used in Parkinson’s disease, in this study it was investigated as a pharmacologic tool to target oncomucin-associated biology in the tumor context. Additional research would be needed before translating this approach to routine clinical care.
Limitations and next steps
As with all translational studies, these findings should be interpreted carefully. Much of the evidence comes from preclinical models, including mouse systems, so confirmation in human patients will be essential. The exact best method to target oncomucins clinically is not yet established, and the safety, dosing, and durability of such a strategy remain unknown. In addition, pancreatic cancer is biologically heterogeneous, so not every patient may have the same mucin-driven immune phenotype.
Future studies should focus on validating oncomucin signatures in larger patient cohorts, determining whether these markers can predict response to KRAS inhibitors, and testing more direct or selective oncomucin-targeting agents. It will also be important to examine whether this pathway interacts with other immunotherapies, such as checkpoint blockade, stromal targeting, or myeloid-cell modulation.
Bottom line
This research shows that MUC4, MUC16, and MUC5AC are not merely bystanders in pancreatic cancer. They help drive immune suppression through EGFR and UNC5B signaling and can reduce the effectiveness of KRAS G12D inhibition by promoting tumor immune escape. Targeting oncomucin-driven immunosuppression may therefore represent a promising new strategy to improve treatment outcomes in pancreatic ductal adenocarcinoma.